Drugs / MF101
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01300078 | Mar → Jun 2011 | — | Bionovo | Unknown | No outcome recorded |
| Phase 1 | NCT00453297 | Oct 2006 → Apr 2007 | — | Bionovo | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00119665 | Feb 2006 → Feb 2007 | — | Bionovo | Completed | No outcome recorded |
| Phase 2 | NCT00454441 | Feb 2006 → Feb 2007 | premature menopause, sleep disorder | Bionovo | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00906308 | Oct 2011 → Feb 2013 | flushing of ears and somnolence, vasomotor rhinitis | Bionovo | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MF101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01300078 ↗ |
| Action | Activate | “Estrogen receptor beta agonist” CHEMBL3545411 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “MF101 (a combination of Chinese herbs)” NCT00454441 ↗ |
| Route | Oral | “MF101 will be administered as a single oral dose” NCT00453297 ↗ |
| Target | ESR2 | “Estrogen receptor beta agonist” CHEMBL3545411 ↗ |